Blood cell manufacture: current methods and future challenges

Area of Science:

• Biotechnology
• Hematology
• Regenerative Medicine

Background:

• Blood transfusions rely on donor availability, prompting research into stem cell-derived blood products.
• Safety and supply concerns drive the development of manufacturing methods for red blood cells (RBCs) and platelets.

Purpose of the Study:

• To evaluate the feasibility of large-scale blood product manufacturing from stem cells.
• To identify challenges and potential solutions for producing therapeutic blood components.

Main Methods:

• Review of current stem cell differentiation protocols for blood cell production.
• Analysis of yield, scalability, and economic factors for manufacturing red blood cells (RBCs) and platelets.
• Exploration of 'blood pharming' concepts for neutrophil production.

Main Results:

• Current stem cell manufacturing methods yield insufficient quantities of RBCs and platelets for significant supply impact.
• The required scale for routine blood product manufacture (10^19 RBC/year) presents substantial technical and logistical hurdles.
• Limited production of neutrophils via 'blood pharming' may be achievable in the near future.

Conclusions:

• Large-scale manufacturing of red blood cells and platelets from stem cells faces significant challenges in yield and scale.
• Near-term applications may involve limited production of specific blood components like neutrophils.
• Further innovation is required to overcome the barriers to routine stem cell-based blood manufacturing.